Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer – Ferring Pharmaceuticals
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Manufacturer clarification response – Updated Results
05 - Manufacturer clarification response – Updated Results Until Death
07 - Consultee submission – British Association of Urological Surgeons
08 - Consultee submission – British Uro-Oncology Group
09 - Consultee submission – Prostate Cancer Support Federation
10 - Consultee submission – Prostate Cancer UK
10 - Consultee submission – Royal College of Physicians
11 – Patient expert personal perspective – Baxter –Smith
12 – Clinical expert personal perspective – Heather Payne
13 – Clinical expert personal perspective – Isabel Syndikus
13 – Patient expert personal perspective – Stuart Watson
14 - Evidence Review Group report prepared by School of Health and Related Research (ScHARR)
15 - Evidence Review Group report Erratum prepared by School of Health and Related Research (ScHARR)
16 - Manufacturer factual accuracy check of Evidence Review Group report
17 – Journal article from European Urology
18 - Evidence Review Group response to query on PSA progression or death
18 - Evidence Review Group additional analyses
19 - Evidence Review Group corrections to the manufacturer’s economic model and incorporation of Committee’s preferred assumptions
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report
27 December 2013 (12.21 Mb 42 sec) |
This page was last updated: 20 December 2013